These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38445848)

  • 21. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
    Kim DY; Yoon KT; Kim W; Lee JI; Hong SH; Lee D; Jang JW; Choi JW; Kim I; Paik YH
    Medicine (Baltimore); 2016 Jul; 95(30):e3896. PubMed ID: 27472670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents.
    Chen Q; Ayer T; Adee MG; Wang X; Kanwal F; Chhatwal J
    JAMA Netw Open; 2020 Nov; 3(11):e2021173. PubMed ID: 33206188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
    Dhiman RK; Grover GS; Premkumar M; Taneja S; Duseja A; Arora S; Rathi S; Satsangi S; Roy A;
    J Hepatol; 2019 Dec; 71(6):1076-1085. PubMed ID: 31325468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals.
    Bartlett SR; Yu A; Chapinal N; Rossi C; Butt Z; Wong S; Darvishian M; Gilbert M; Wong J; Binka M; Alvarez M; Tyndall M; Krajden M; Janjua NZ
    Liver Int; 2019 Dec; 39(12):2261-2272. PubMed ID: 31444846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
    Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
    BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study.
    Nam JY; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Bae SH; Ki M; Choi HY; Lee EY; Jeong SH
    Gut Liver; 2020 Mar; 14(2):207-217. PubMed ID: 31158950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease burden of chronic hepatitis C in Brazil.
    Ferreira PR; Brandão-Mello CE; Estes C; Gonçales Júnior FL; Coelho HS; Razavi H; Cheinquer H; Wolff FH; Ferraz ML; Pessoa MG; Mendes-Correa MC
    Braz J Infect Dis; 2015; 19(4):363-8. PubMed ID: 26051505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
    Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
    Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).
    Janjua NZ; Kuo M; Yu A; Alvarez M; Wong S; Cook D; Wong J; Grebely J; Butt ZA; Samji H; Ramji A; Tyndall M; Krajden M
    EBioMedicine; 2016 Oct; 12():189-195. PubMed ID: 27596150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P
    J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
    Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
    Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hospitalizations in Immigrants and Nonimmigrants Diagnosed With Chronic Hepatitis C Infection in Québec.
    Kamstra R; Azoulay L; Steele R; Klein MB; Greenaway C
    Clin Infect Dis; 2016 Dec; 63(11):1439-1448. PubMed ID: 27501843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.
    Kondili LA; Andreoni M; Alberti A; Lobello S; Babudieri S; De Michina A; Merolla R; Marrocco W; Craxì A
    BMC Infect Dis; 2022 Jan; 22(1):58. PubMed ID: 35038987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.